Reaffirmed: Cambrex Corp (NYSE:CBM) Buy Rating Reiterated by Analysts at Craig-Hallum; $60.0 Target in Place

January 21, 2018 - By Winifred Garcia

 Reaffirmed: Cambrex Corp (NYSE:CBM) Buy Rating Reiterated by Analysts at Craig Hallum; $60.0 Target in Place

Investors sentiment increased to 1.58 in Q3 2017. Its up 0.59, from 0.99 in 2017Q2. It is positive, as 18 investors sold Cambrex Corporation shares while 61 reduced holdings. 41 funds opened positions while 84 raised stakes. 31.63 million shares or 2.69% more from 30.80 million shares in 2017Q2 were reported.

Comerica Bankshares reported 81,112 shares stake. American Mgmt reported 565,658 shares. Scout Investments holds 0.12% or 80,500 shares. Truenorth reported 65,344 shares. Campbell Newman Asset Mgmt invested in 0.09% or 9,006 shares. 161,500 are held by Renaissance Ltd Com. Voya Invest Management Limited Liability Company holds 0% or 32,674 shares in its portfolio. Lsv Asset Mngmt owns 5,600 shares. Mason Street Ltd Liability Corp holds 0.01% or 8,289 shares. Thrivent Fincl For Lutherans holds 0% or 19,980 shares in its portfolio. Bnp Paribas Arbitrage Sa reported 0% stake. 31 were accumulated by Contravisory Invest Management Inc. One Trading L P holds 0% or 2,074 shares in its portfolio. Capstone Limited Liability Company holds 4,800 shares. Moreover, Torray Llc has 0.04% invested in Cambrex Corporation (NYSE:CBM).

Since August 1, 2017, it had 0 buys, and 3 sales for $1.57 million activity.

Cambrex Corp (NYSE:CBM) Rating Reaffirmed

Craig-Hallum now has a $60.0 TP on shares of Cambrex Corp (NYSE:CBM). The TP would suggest a potential upside of 6.57 % from the current price of Cambrex Corp (NYSE:CBM). This rating was revealed in analysts report on Tuesday morning.

Investors sentiment increased to 1.58 in Q3 2017. Its up 0.59, from 0.99 in 2017Q2. It is positive, as 18 investors sold Cambrex Corporation shares while 61 reduced holdings. 41 funds opened positions while 84 raised stakes. 31.63 million shares or 2.69% more from 30.80 million shares in 2017Q2 were reported.

Comerica Bankshares reported 81,112 shares stake. American Mgmt reported 565,658 shares. Scout Investments holds 0.12% or 80,500 shares. Truenorth reported 65,344 shares. Campbell Newman Asset Mgmt invested in 0.09% or 9,006 shares. 161,500 are held by Renaissance Ltd Com. Voya Invest Management Limited Liability Company holds 0% or 32,674 shares in its portfolio. Lsv Asset Mngmt owns 5,600 shares. Mason Street Ltd Liability Corp holds 0.01% or 8,289 shares. Thrivent Fincl For Lutherans holds 0% or 19,980 shares in its portfolio. Bnp Paribas Arbitrage Sa reported 0% stake. 31 were accumulated by Contravisory Invest Management Inc. One Trading L P holds 0% or 2,074 shares in its portfolio. Capstone Limited Liability Company holds 4,800 shares. Moreover, Torray Llc has 0.04% invested in Cambrex Corporation (NYSE:CBM).

Since August 1, 2017, it had 0 buys, and 3 sales for $1.57 million activity.

Cambrex Corporation (NYSE:CBM) Ratings Coverage

Among 6 analysts covering Cambrex Corp (NYSE:CBM), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cambrex Corp has $66 highest and $54 lowest target. $60.20’s average target is 6.93% above currents $56.3 stock price. Cambrex Corp had 7 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, October 31 by Craig Hallum. First Analysis maintained the shares of CBM in report on Tuesday, January 17 with “Overweight” rating. The firm has “Overweight” rating by First Analysis given on Monday, November 7. The firm has “Overweight” rating given on Tuesday, July 21 by Stephens. William Blair maintained the shares of CBM in report on Tuesday, January 16 with “Buy” rating. The stock has “Buy” rating by Singular Research on Thursday, February 11.

The stock increased 0.54% or $0.3 during the last trading session, reaching $56.3. About 304,025 shares traded. Cambrex Corporation (NYSE:CBM) has risen 11.15% since January 21, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Analysts await Cambrex Corporation (NYSE:CBM) to report earnings on February, 2. They expect $1.11 earnings per share, down 5.93 % or $0.07 from last year’s $1.18 per share. CBM’s profit will be $36.38M for 12.68 P/E if the $1.11 EPS becomes a reality. After $0.55 actual earnings per share reported by Cambrex Corporation for the previous quarter, Wall Street now forecasts 101.82 % EPS growth.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.85 billion. The company's products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 18.85 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Another recent and important Cambrex Corporation (NYSE:CBM) news was published by Globenewswire.com which published an article titled: “Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at …” on January 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.